This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
ILD related to systemic autoimmune disease
ILD_SYST_AUTO
interstitial lung disease: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of pulmonary alveoli that extends to the interstitium and beyond leading to diffuse pulmonary fibrosis. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditions
|
188 |
3. Check pre-conditions, main-only, mode, registry filtersNone 0 out of 7 registries used, show all original rules. |
0 |
4. Check minimum number of eventsNone |
0 |
5. Include endpoints |
171 |
6. Filter based on genotype QC (FinnGen only) |
168 |
Control definitions (FinnGen only)
- Control exclude
- ILD_ENDPOINTS
- Control conditions
- not ILD_ELSEWHERE
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
ILD related to systemic autoimmune disease
based on the number of shared cases.
Similar with more cases:
- ILD and respiratory illness in diseases classified elsewhere
- Respiratory disorders in diseases classified elsewhere
- Interstitial lung disease
- Other interstitial pulmonary diseases
- Interstitial lung disease endpoints
Similar with less cases:
None
Case counts by codes
↥FinnGen case counts by registry codes:
No data for upset plot.
No data for upset table.
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 702 | 418 | 283 |
| Only index persons | 570 | 342 | 228 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 65.09 | 64.63 | 65.84 |
| Only index persons | 64.33 | 63.09 | 66.19 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 168 | 95 | 73 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 61.77 | 59.61 | 64.59 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 171
- Matched controls
- 1710
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
52.7
154.9
134
110
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
55.0
145.9
95
38
L04AX01
ATC
azathioprine; systemic
59.7
134.1
82
26
P01BA02
ATC
hydroxychloroquine; oral
31.6
121.5
107
86
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
+∞
110.8
94
*
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
1901.8
104.8
91
*
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
24.3
90.6
78
57
TGC00
NOMESCO Finland
Bronchial lavation
37.4
83.7
56
22
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
23.9
81.5
68
46
UGC12
NOMESCO Finland
Flexible bronchoscopy
17.6
74.6
77
76
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
32.6
73.4
51
22
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
45.2
71.2
44
13
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
+∞
70.9
63
*
J99.0*M05.1
ICD-10 Finland
Rheumatoid lung disease
+∞
60.0
54
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
12.3
58.5
79
112
L04AX03
ATC
methotrexate; systemic
12.9
57.5
71
89
H02AB06
ATC
prednisolone; systemic
39.5
55.0
164
636
L01BA01
ATC
methotrexate; systemic
24.2
53.5
41
22
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
13.8
51.7
57
60
A07EC01
ATC
sulfasalazine; oral, rectal
12.9
51.2
60
69
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
13.9
49.9
54
55
L04AA06
ATC
mycophenolic acid; systemic
89.9
47.3
51
8
J18.9
ICD-10 Finland
Pneumonia, unspecified
8.8
45.7
110
291
GD1AD
NOMESCO Finland
Thorax CT examination
13.9
43.9
46
44
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
19.4
43.9
37
24
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
10.0
42.3
135
465
XG410
NOMESCO Finland
Flow-volume spirometry
15.5
38.8
37
30
J99.0
ICD-10 Finland
Rheumatoid lung disease
+∞
34.6
32
*
J99.1*M35.0
ICD-10 Finland
Respiratory disorders in sicca syndrome [Sjögren]
+∞
34.6
32
*
L88
ICPC
Rheumatoid/seropositive arthritis
15.6
33.2
31
24
J99.1
ICD-10 Finland
Respiratory disorders in other diffuse connective tissue disorders
+∞
31.2
29
*
M05BA04
ATC
alendronic acid; oral
7.6
29.4
51
91
GD1AA
NOMESCO Finland
Thorax X-ray examination
6.4
26.0
133
607
J99.1*M31.3
ICD-10 Finland
Respiratory disorders in Wegener's granulomatosis
+∞
24.6
23
*
R50.9
ICD-10 Finland
Fever, unspecified
5.5
23.2
58
145
L04AA13
ATC
[U] leflunomide
25.9
23.2
32
15
J01MA14
ATC
moxifloxacin; systemic
6.4
23.1
46
93
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
6.9
22.8
41
75
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
45.4
22.5
27
7
M05.1
ICD-10 Finland
Rheumatoid lung disease
+∞
22.4
21
*
M05.9
ICD-10 Finland
Seropositive rheumatoid arthritis, unspecified
22.8
22.3
32
17
R06.0
ICD-10 Finland
Dyspnoea
4.6
22.2
91
337
ZX120
NOMESCO Finland
Intravenous
5.9
21.9
48
106
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
21.3
20
*
M33.2
ICD-10 Finland
Polymyositis
237.8
21.1
21
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
4.1
18.3
80
303
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
7.4
18.2
29
46
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.3
16.6
31
58
M31.3
ICD-10 Finland
Wegener granulomatosis
66.6
16.1
18
*
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
5.5
16.0
35
76
J01MA12
ATC
levofloxacin; systemic
4.0
15.7
62
215
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
14.8
14
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.7
14.7
66
248
J96.1
ICD-10 Finland
Chronic respiratory failure
22.4
14.2
20
10
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
6.8
13.8
23
38
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.6
13.8
38
100
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.7
13.7
36
91
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
14.7
13.4
22
17
NH3EA
NOMESCO Finland
Feet X-ray examination with load
19.2
12.8
19
11
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
14.8
12.8
21
16
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
35.0
12.8
16
5
J99.1*M32.1
ICD-10 Finland
Respiratory disorders in systemic: lupus erythematosus
+∞
12.7
12
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.1
12.6
42
127
M33.1
ICD-10 Finland
Other dermatomyositis
139.8
12.6
13
*
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.3
12.4
37
103
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
3.4
12.0
57
219
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
32.6
11.9
15
5
C03CA01
ATC
furosemide; systemic
3.1
11.8
80
378
H02AB07
ATC
prednisone; oral
3.8
11.7
42
134
L04AD01
ATC
ciclosporin; systemic
19.4
11.0
16
9
WZC30
NOMESCO Finland
Teaching
3.3
10.9
51
193
R03AK08
ATC
formoterol and beclometasone; inhalant
8.7
10.8
23
30
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.9
10.6
102
575
M05BX04
ATC
denosumab; parenteral
4.7
10.6
27
66
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
11.7
10.6
19
18
GX1K5
NOMESCO Finland
Diffusion capacity
116.9
10.5
11
*
M80.4
ICD-10 Finland
Drug-induced osteoporosis with pathological fracture
34.9
10.5
13
*
SPAT1255
SPAT
Intravenous administration of medicine
4.9
10.4
25
58
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
25.2
10.4
14
6
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
9.4
10.4
21
25
SPAT1229
SPAT
Assessment of need for aid
4.5
10.3
28
72
M13.9
ICD-10 Finland
Arthritis, unspecified
4.4
10.1
28
73
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.3
10.0
47
177
H04.10
ICD-10 Finland
Dry eye syndrome
3.6
9.8
37
121
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.1
9.7
52
212
ND2BA
NOMESCO Finland
Hand and fingers extensive X-ray examination
13.4
9.6
16
13
M01CB01
ATC
sodium aurothiomalate; parenteral
32.0
9.5
12
*
U07.1
ICD-10 Finland
Emergency use of U07.1 | COVID-19, virus identified
3.4
9.5
41
146
TNB11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in shoulder joint
+∞
9.5
9
*
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
9.5
9
*
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
3.9
9.4
31
92
R81
ICPC
Pneumonia
8.2
9.2
20
27
R03BA08
ATC
ciclesonide; inhalant
3.8
8.8
30
91
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
52.8
8.8
10
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.1
8.8
46
184
L04AA01
ATC
[U] ciclosporin
21.4
8.6
12
6
J01AA02
ATC
doxycycline; systemic
4.0
8.3
152
1142
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.4
8.3
34
117
TFC00
NOMESCO Finland
Catheterisation of right atrium or ventricle
18.3
8.2
12
7
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.5
7.9
70
366
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
7.3
7.8
18
27
J01FA06
ATC
roxithromycin; oral
2.5
7.7
89
523
NA1EA
NOMESCO Finland
Cervical spine X-ray examination with flexion
19.5
7.7
11
6
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
26.4
7.7
10
*
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.9
7.6
24
69
R03AC02
ATC
salbutamol; inhalant
2.5
7.5
113
746
Z01.8
ICD-10 Finland
Other specified special examinations
2.7
7.5
51
233
GX1D5
NOMESCO Finland
Flow volume spirometry
83.6
7.5
8
*
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
11.6
7.4
13
12
M32.1
ICD-10 Finland
Systemic lupus erythematosus with organ or system involvement
+∞
7.3
7
*
M31.1
ICD-10 Finland
Thrombotic microangiopathy
+∞
7.3
7
*
M31.8
ICD-10 Finland
Other specified necrotizing vasculopathies
+∞
7.3
7
*
L04AB01
ATC
etanercept; parenteral
16.7
7.3
11
7
A02BC02
ATC
pantoprazole; systemic
2.8
7.2
134
968
L01AA01
ATC
cyclophosphamide; systemic
31.5
7.2
9
*
ZX108
NOMESCO Finland
Inhalation
31.5
7.2
9
*
M81.4
ICD-10 Finland
Drug-induced osteoporosis
31.5
7.2
9
*
GDA11
NOMESCO Finland
Thoracoscopic biopsy of lung
31.5
7.2
9
*
R28
ICPC
Limited function/disability (R)
14.6
7.0
11
8
SPAT1249
SPAT
Treatment-related counselling outside office
2.4
6.9
80
465
NH3DA
NOMESCO Finland
Bilateral foot X-ray examination
11.6
6.9
12
11
XCW99
NOMESCO Finland
Other investigative procedure of eye
3.2
6.8
30
107
M10.9
ICD-10 Finland
Gout, unspecified
3.9
6.8
21
59
M34.9
ICD-10 Finland
Systemic sclerosis, unspecified
41.8
6.8
8
*
R60.9
ICD-10 Finland
Oedema, unspecified
4.5
6.7
17
41
B01AA03
ATC
warfarin; systemic
2.6
6.6
46
212
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.7
6.5
43
192
GX2C5
NOMESCO Finland
Short-lasting oximetry
72.4
6.5
7
*
J17.3*B59
ICD-10 Finland
Pneumonia due to Pneumocystis carinii
72.4
6.5
7
*
M32.8
ICD-10 Finland
Other forms of systemic lupus erythematosus
72.4
6.5
7
*
I50.9
ICD-10 Finland
Heart failure, unspecified
2.8
6.4
36
148
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
11.7
6.4
11
10
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
3.7
6.4
21
62
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.2
6.4
28
100
J01FF01
ATC
clindamycin; systemic
2.4
6.3
59
310
E13.9
ICD-10 Finland
Other specified diabetes mellitus, without complications
27.8
6.3
8
*
M34.0
ICD-10 Finland
Progressive systemic sclerosis
+∞
6.3
6
*
GD1BT
NOMESCO Finland
Biopsy of lung with X-ray guidance
+∞
6.3
6
*
XF614
NOMESCO Finland
Measurement of pulmonary artery pressure
+∞
6.3
6
*
WX726
NOMESCO Finland
High-flow oxygen therapy
+∞
6.3
6
*
N08.5*M31.3
ICD-10 Finland
Glomerular disorders in Wegener's granulomatosis
+∞
6.3
6
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.0
6.2
30
113
7140A
ICD-9 Finland
Rheumatoid arthritis and other inflammatory polyarthropathies, Rheumatoid arthritis[ARTHRITIS RHEUMATOIDES SEROPOSITIVA]
13.2
6.2
10
8
NG1DA
NOMESCO Finland
X-ray of knees
10.6
6.1
11
11
H02AB04
ATC
methylprednisolone; systemic
2.7
6.1
36
152
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
61
48
19.20
66.83
3.7
1.4
—
—
—
0
0
57
49
16.95
59.00
2.9
1.3
1.21
1.19
g/l
0.20
57
49
55
49
16.07
55.56
3.8
2.4
—
—
—
0
0
50
38
18.18
55.24
1.7
1.2
2.30
1.62
u/ml
—
21
5
45
31
19.34
52.19
1.6
1.2
47.17
—
u/ml
—
7
0
44
29
20.08
52.17
1.5
1.2
18.18
—
u/ml
—
10
0
37
23
20.25
44.85
2.4
1.7
—
—
—
0
0
39
28
17.75
43.96
2.3
1.7
—
—
—
0
0
43
44
12.72
39.11
1.8
1.6
0.76
0.11
iu/ml
—
16
9
41
41
12.84
37.80
2.8
1.6
—
—
—
0
0
89
224
7.20
37.52
3.0
2.0
—
—
—
0
0
39
38
13.00
36.51
2.7
1.6
—
—
—
0
0
38
36
13.29
36.20
2.2
1.3
—
—
—
0
0
40
10
51.61
33.93
2.4
1.6
—
—
—
0
0
31
25
14.92
32.40
2.1
1.8
—
—
—
0
0
32
28
13.83
31.86
2.7
1.6
—
—
—
0
0
84
238
5.97
30.11
1.5
1.3
103.58
38.30
iu/ml
1.29
51
77
68
164
6.22
28.98
2.5
1.8
—
—
—
0
0
161
830
17.07
28.93
26.2
9.5
5.41
4.08
e9/l
8.46
161
728
141
644
7.78
28.61
23.0
5.6
65.29
57.05
%
11.50
141
609
68
167
6.10
28.35
2.7
1.9
—
—
—
0
0
141
651
7.65
28.04
24.7
5.8
20.71
27.89
%
14.02
141
614
30
31
11.52
26.68
2.5
1.5
394.29
—
titre
—
7
0
78
229
5.42
26.29
1.5
1.3
64.08
9.21
u/ml
2.29
33
87
108
433
5.06
24.30
6.9
2.0
101.01
216.48
u/l
1.95
103
411
61
169
5.06
21.49
10.1
7.6
1.62
1.18
mmol/l
0.33
50
144
31
18
20.73
20.97
1.5
1.3
42.40
—
u/ml
—
7
0
27
34
9.24
20.63
1.8
1.2
—
—
—
0
0
162
1075
10.63
20.41
22.1
4.2
22.27
12.10
mm/h
8.83
162
976
28
38
8.62
20.15
2.1
1.4
—
—
—
0
0
135
714
5.23
19.60
10.3
6.7
1.21
1.22
mmol/l
1.57
119
599
30
21
17.05
18.96
2.2
1.8
—
—
—
0
0
37
78
5.78
17.55
6.6
3.1
2.33
2.06
mmol/l
0.18
30
57
115
573
4.07
17.29
3.5
2.3
82.24
78.04
nmol/l
0.90
110
500
129
704
4.39
16.80
11.3
5.0
0.00
0.00
estimate
-0.00
43
148
130
715
4.41
16.70
9.1
3.8
0.00
0.00
estimate
-0.00
43
143
128
699
4.31
16.55
9.1
3.8
0.00
0.01
estimate
0.50
44
158
27
21
15.02
16.34
1.3
1.1
—
—
—
0
0
41
110
4.59
14.56
10.5
6.4
8.66
9.65
mmol/l
0.60
41
102
111
589
3.52
14.13
6.3
3.9
54.62
34.22
ng/l
0.61
100
425
25
23
12.52
14.06
3.5
1.4
—
—
—
0
0
26
27
11.15
13.80
5.3
4.6
61.88
59.81
%
0.24
26
27
26
27
11.15
13.80
2.2
1.7
—
—
—
0
0
26
27
11.15
13.80
2.2
1.7
—
—
—
0
0
17
5
37.46
13.79
1.8
1.4
—
—
—
0
0
19
9
23.54
13.67
3.5
2.9
—
—
—
0
0
25
27
10.64
13.01
5.2
3.9
4.48
4.98
e9/l
0.33
25
27
84
400
3.16
12.37
10.4
4.0
0.00
0.00
estimate
-0.00
43
142
100
529
3.14
12.20
8.8
2.9
—
—
—
0
0
21
19
12.42
11.92
3.5
1.3
—
—
—
0
0
159
1152
6.42
11.17
23.5
7.3
70.64
78.68
u/l
2.55
159
1069
17
14
13.33
10.10
1.5
2.1
—
—
—
0
0
17
14
13.33
10.10
1.5
2.1
—
—
—
0
0
17
14
13.33
10.10
1.5
2.1
—
—
—
0
0
115
703
2.94
10.08
24.0
12.9
1.29
1.27
inr
0.08
45
212
66
312
2.82
9.34
2.2
1.8
1.53
1.36
mg/l
0.13
54
251
79
410
2.72
9.32
7.4
2.9
0.43
0.44
e6/l
0.01
72
302
16
14
12.47
9.28
1.9
2.1
—
—
—
0
0
47
186
3.11
9.15
14.1
7.3
103.77
104.16
mmol/l
0.21
47
186
96
555
2.66
9.04
10.5
3.9
—
—
—
0
0
21
48
4.85
8.89
1.1
4.5
53.00
50.02
mg/l
0.09
15
36
21
48
4.85
8.89
1.1
4.5
70.21
27.26
mg/l
0.57
15
36
14
10
15.11
8.86
3.2
1.3
—
—
—
0
0
14
10
15.11
8.86
3.2
1.3
—
—
—
0
0
16
16
10.90
8.74
1.9
1.9
—
—
—
0
0
15
14
11.62
8.48
3.5
1.3
—
—
—
0
0
14
12
12.58
8.24
3.2
1.4
—
—
—
0
0
19
29
7.23
8.16
4.3
2.3
14.36
16.54
%
—
10
14
19
43
4.85
8.12
2.7
2.2
—
—
—
0
0
35
126
3.24
7.91
3.4
3.7
2.96
2.12
mmol/l
0.65
30
102
15
17
9.55
7.72
2.8
1.7
—
—
—
0
0
15
17
9.55
7.72
2.8
1.7
—
—
—
0
0
31
106
3.35
7.59
1.7
1.5
—
—
—
0
0
25
75
3.73
7.44
2.0
2.0
—
—
—
0
0
47
207
2.75
7.40
3.4
2.3
2.31
2.30
g/l
0.03
47
185
10
5
21.10
7.22
1.2
1.0
7.48
11.25
ug/l
—
10
5
33
123
3.09
7.00
4.8
2.6
58.44
61.47
ml/min/173m2
0.21
18
51
21
59
3.92
6.83
1.5
2.4
—
—
—
0
0
26
85
3.43
6.81
21.5
7.1
26.60
25.22
mmol/l
0.90
26
85
17
31
5.97
6.50
4.2
1.9
118.64
128.50
g/l
0.81
11
22
13
16
8.69
6.46
2.5
2.2
87.12
88.91
%
0.47
13
16
11
10
11.65
6.39
1.4
1.8
—
—
—
0
0
11
10
11.65
6.39
1.4
1.8
—
—
—
0
0
17
32
5.78
6.35
12.5
3.0
5.14
5.04
kpa
0.18
17
32
14
21
7.16
6.18
1.1
1.2
1.60
1.00
u/ml
—
5
5
11
11
10.59
6.13
1.0
1.2
—
—
—
0
0
57
300
2.35
6.06
1.3
1.2
0.69
1.60
u/ml
0.76
22
85
16
40
4.31
6.05
2.4
2.0
—
—
—
0
0
12
15
8.51
5.95
1.3
1.2
—
—
—
0
0
12
15
8.51
5.95
1.3
1.2
—
—
—
0
0
12
16
7.97
5.74
1.3
1.2
—
—
—
0
0
12
16
7.97
5.74
1.3
1.2
—
—
—
0
0
12
16
7.97
5.74
1.3
1.2
—
—
—
0
0
17
47
3.91
5.64
1.4
1.1
—
—
—
0
0
21
68
3.38
5.56
4.0
2.6
1.67
1.13
%
1.21
21
68
12
17
7.50
5.54
2.8
3.8
—
—
—
0
0
8
5
16.67
5.46
2.9
1.6
62.69
63.80
ug/l
—
8
5
10
11
9.57
5.36
1.1
1.1
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
16
44
3.91
5.34
8.0
2.0
0.37
0.39
u/ml
—
8
22
20
66
3.30
5.14
3.7
2.6
0.70
0.64
%
0.33
20
66
10
12
8.77
5.13
1.4
1.1
—
—
—
0
0
13
24
5.77
5.02
1.2
1.2
2.00
5.82
u/ml
—
5
11
105
744
2.07
4.97
3.2
2.6
—
—
—
0
0
22
79
3.05
4.93
1.6
1.2
—
—
—
0
0
16
47
3.65
4.88
1.4
1.1
—
—
—
0
0
8
7
11.91
4.83
1.3
2.0
—
—
—
0
0
8
7
11.91
4.83
1.3
2.0
—
—
—
0
0
8
7
11.91
4.83
1.3
2.0
—
—
—
0
0
47
249
2.22
4.80
4.1
2.5
0.52
1.01
e6/l
1.44
37
135
34
158
2.44
4.67
5.2
3.2
—
—
—
0
0
15
37
4.34
4.53
1.5
1.9
—
—
—
0
0
10
17
6.17
4.19
1.2
1.4
—
—
—
0
0
9
14
6.72
4.04
1.2
1.1
—
—
—
0
0
29
135
2.38
3.95
3.0
2.3
9.70
8.40
ug/l
0.13
24
124
7
8
9.06
3.81
3.9
8.0
—
—
—
0
0
8
12
6.93
3.71
1.6
1.5
—
—
—
0
0
11
25
4.63
3.69
1.4
1.5
—
—
—
0
0
12
30
4.22
3.67
1.4
1.2
—
—
—
0
0
12
30
4.22
3.67
1.4
1.2
—
—
—
0
0
17
63
2.89
3.61
1.4
1.2
—
—
—
0
0
11
26
4.45
3.57
1.5
1.3
—
—
—
0
0
50
301
1.93
3.53
12.6
4.0
1.02
1.02
kg/l
—
6
41
145
1230
2.18
3.38
47.5
17.8
16.39
15.20
%
1.36
145
1214
46
276
1.91
3.26
2.4
2.8
2.46
2.46
mmol/l
0.00
40
241
12
35
3.61
3.18
1.1
1.1
—
—
—
0
0
13
41
3.35
3.13
1.2
1.3
—
—
—
0
0
5
5
10.24
2.99
1.6
1.6
—
—
—
0
0
12
38
3.32
2.92
1.6
1.5
344.00
249.45
ug/g
—
7
20
89
671
1.68
2.82
3.8
2.5
—
—
—
0
0
7
16
4.51
2.50
2.1
1.9
—
—
—
0
0
7
16
4.51
2.50
1.1
1.2
—
—
—
0
0
5
8
6.40
2.38
1.4
1.1
13.00
14.50
u/l
—
5
8
7
17
4.25
2.38
1.9
1.4
—
—
—
0
0
163
1513
2.65
2.36
50.0
17.4
81.33
78.20
umol/l
0.74
163
1513
161
1483
2.46
2.12
42.7
16.9
139.19
139.78
mmol/l
2.08
161
1440
163
1523
2.50
2.09
33.5
10.6
25.30
25.05
u/l
0.06
163
1460
7
20
3.60
2.08
1.1
1.1
—
—
—
0
0
6
15
4.10
2.05
1.0
2.0
—
—
—
0
0
6
15
4.10
2.05
1.0
2.0
—
—
—
0
0
6
15
4.10
2.05
1.0
2.0
—
—
—
0
0
6
15
4.10
2.05
1.0
2.0
—
—
—
0
0
6
15
4.10
2.05
1.0
2.0
—
—
—
0
0
8
26
3.18
2.04
1.1
1.2
—
—
—
0
0
161
1487
2.41
2.03
42.8
17.0
3.97
3.98
mmol/l
0.15
161
1444
9
32
2.91
2.03
1.0
1.6
—
—
—
0
0
10
39
2.66
1.98
1.0
1.1
—
—
—
0
0
5
11
4.65
1.95
1.0
1.0
—
—
—
0
0
6
16
3.85
1.95
1.0
1.9
—
—
—
0
0
9
34
2.74
1.89
1.1
1.3
—
—
—
0
0
74
579
1.49
1.76
2.1
2.0
96.25
96.18
pmol/l
0.00
50
266
10
40
2.59
1.69
4.5
2.0
1.76
1.70
mg/l
—
10
34
46
331
1.53
1.61
3.0
2.3
—
—
—
0
0
32
222
1.54
1.31
2.9
2.0
30.49
29.38
s
0.71
32
214
7
31
2.31
1.11
1.1
1.4
—
—
—
0
0
105
924
1.35
1.11
5.2
2.9
82.28
48.35
u/l
0.49
100
854
5
22
2.31
1.04
1.0
1.1
—
—
—
0
0
163
1566
1.87
0.98
64.2
21.4
4.35
4.49
e12/l
2.94
163
1523
163
1566
1.87
0.98
64.6
21.5
128.93
135.55
g/l
7.55
163
1540
163
1565
1.89
0.98
63.8
21.4
262.61
245.44
e9/l
2.56
163
1529
163
1565
1.89
0.98
64.3
21.5
39.78
40.12
%
0.46
155
1460
6
28
2.18
0.92
1.0
1.4
—
222.41
—
0
9
31
233
1.40
0.87
6.1
2.7
2.25
2.72
e6/l
0.14
22
122
50
408
1.32
0.85
1.7
1.8
1.54
1.30
mmol/l
1.54
42
341
5
95
0.51
0.68
2.0
1.8
—
—
—
0
0
55
477
1.23
0.56
6.4
3.8
9.27
8.02
mg/mmol
0.13
43
289
143
1366
1.29
0.55
37.2
14.1
77.37
78.07
ml/min/173m2
0.14
136
1125
7
47
1.51
0.48
1.0
1.3
—
—
—
0
0
23
281
0.79
0.43
3.1
3.2
0.64
0.77
ug/l
0.58
17
189
24
196
1.26
0.42
1.4
1.4
—
—
—
0
0
136
1406
0.84
0.35
4.9
4.7
5.76
6.02
mmol/l
2.43
129
1278
8
66
1.22
0.27
1.4
1.0
—
—
—
0
0
133
1368
0.88
0.26
4.5
4.2
1.43
1.27
mmol/l
2.33
128
1235
0
10
0.00
0.21
0.0
1.2
—
177.35
—
0
10
0
13
0.00
0.21
0.0
1.0
—
41.88
—
0
8
0
13
0.00
0.21
0.0
1.0
—
451.75
—
0
8
9
80
1.13
0.15
1.0
2.0
—
—
—
0
0
139
1412
0.92
0.12
4.9
4.7
1.43
1.49
mmol/l
0.96
130
1283
36
375
0.95
0.06
3.7
4.9
23.72
21.70
%
0.38
22
193
19
178
1.08
0.06
11.4
8.1
—
—
—
0
0
141
1419
0.96
0.02
4.9
4.8
4.45
4.68
mmol/l
1.79
131
1299
146
1454
1.03
0.00
5.3
5.4
2.55
2.75
mmol/l
1.85
137
1321
47
469
1.00
0.00
3.8
5.3
1.75
2.93
ug/l
0.97
42
416
13
135
0.96
0.00
1.6
2.5
37.08
34.54
u/l
0.16
13
112
18
182
0.99
0.00
1.4
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
0.33
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
72
0.97
-0.00
1.0
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint ILD_SYST_AUTO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ILD_SYST_AUTO | 3.699 [2.83, 4.84] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.096 |
During the follow-up period (1.1.1998 — 31.12.2019), 137 out of 320 females with ILD_SYST_AUTO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ILD_SYST_AUTO | 3.464 [2.4, 5.01] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.006 |
During the follow-up period (1.1.1998 — 31.12.2019), 108 out of 205 males with ILD_SYST_AUTO died.
Mortality risk
Mortality risk for people of age
years, who have ILD_SYST_AUTO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.408% | 0.714% |
| 5 | 1.999% | 4.234% |
| 10 | 4.769% | 9.531% |
| 15 | 9.366% | 17.667% |
| 20 | 16.266% | 28.289% |
Relationships between endpoints
↥Index endpoint: ILD_SYST_AUTO – ILD related to systemic autoimmune disease
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data